Table 4. Summary of recent clinical trial studies of nanomedicines for lung cancer therapeutics.

NSCLC: Non-small cell lung cancer; DHA: Docosahexaenoic acid.

Active Drug	Nanomaterial Types	Types of Lung Cancer	Phase	Reference
Paclitaxel	Nanoparticle albumin-based (Nab)	Non-squamous NSCLC	III	[10,11]
		NSCLC	III
Docetaxel (DTX)	Polymeric	Advanced or metastatic cancer, including lung cancer	I	[5,11]
		NSCLC	II
Camptothecin	Polymeric	NSCLC	II	[11]
		Lung neoplasms, small cell lung cancer	I/II	[3]
	Cyclodextrin-based polymer	NSCLC	II	[5]
Hafnium oxide-containing nanoparticles		NSCLC	I	[11]
		Recurrent NSCLC	I
Irinotecan	Polymeric	NSCLC	II	[11]
		Lung and breast cancer	II
		Recurrent small cell lung carcinoma	II
	Liposome	Small cell lung cancer	I/II/III	[3]
Paclitaxel	Polymeric micelle	NSCLC	II	[11]
		NSCLC	III	[3]
Cisplatin	Micellar	Solid tumors	I/II	[11]
SN-38	Polymeric micelle	Small cell lung cancer	II	[11]
Topotecan	Liposomal	Small cell lung cancer	II/III	[11]
DHA-bonded paclitaxel		NSCLC	III	[11]
Gold	Silica-Gold	Lung cancer	I	[3]
Docetaxel	Prostate-specific membrane antigen (PSMA) – targeting polymer	NSCLC	II	[5]